Pharmacokinetic/pharmacodynamic modeling of cardiac toxicity in human acute overdoses: Utility and limitations

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 5, 2008, Pages 569-579

  Mégarbane, Bruno ^a   Aslani, Arsia Amir ^b   Deye, Nicolas ^a   Baud, Frédéric J ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS 1 PANTHÉON SORBONNE   (France)

Author keywords

Antidote; Cardiac failure; Cardiac toxicity; Citalopram; Conduction disturbance; Cyanide; Digitalis; Dysrhytmia; Hypotension; Pharmacokinetic pharmacodynamic relationship; Poisoning; Venlafaxine

Indexed keywords

ACTIVATED CARBON; ADRENALIN; ANTIDEPRESSANT AGENT; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CISAPRIDE; CITALOPRAM; COLCHICINE; CYANIDE; DIGITALIS; DOFETILIDE; GREPAFLOXACIN; HYDROXOCOBALAMIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MEPROBAMATE; QUETIAPINE; STEROID; TERFENADINE; VENLAFAXINE;

BLOOD TOXICITY; CARDIOTOXICITY; COMPUTER PREDICTION; CORRELATION ANALYSIS; CYANIDE POISONING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; GENETIC ALGORITHM; HUMAN; HYPOTENSION; INDIVIDUALIZATION; PHARMACODYNAMICS; POPULATION RESEARCH; QT PROLONGATION; RESUSCITATION; REVIEW; SHOCK; SINGLE DRUG DOSE; STATISTICAL MODEL; TOXICITY TESTING;

ACUTE DISEASE; ANIMALS; HEART DISEASES; HUMANS; MODELS, BIOLOGICAL; OVERDOSE; PHARMACOKINETICS;

EID: 45949088864     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.5.569     Document Type: Review

References (52)

1. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) 2006;44:803-932
2. Baud FJ. Pharmacokinetic-pharmacodynamic relationships. How are they useful in human toxicology? Toxicol Lett 1998;102-3:643-8
3. Albertson TE, Dawson A, de Latorre F, et al. TOX-ACLS: toxicologic-oriented advanced cardiac life support. Ann Emerg Med 2001;37:S78-90
4. Delk C, Holstege CP, Brady WJ. Electrocardiographic abnormalities associated with poisoning. Am J Emerg Med 2007;25:672-87
5. Love JN, Enlow B, Howell JM, et al. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med 2002;40:603-10
6. Singh N, Singh HK, Khan IA. Serial electrocardiographic changes as a predictor of cardiovascular toxicity in acute tricyclic antidepressant overdose. Am J Ther 2002;9:75-9
7. Baud FJ. Cyanide: critical issues in diagnosis and treatment. Hum Exp Toxicol 2007;26:191-201
8. Baud FJ, Borron SW, Megarbane B, et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med 2002;30:2044-50
9. Koppel C, Oberdisse U, Heinemeyer G. Clinical course and outcome in class IC antiarrhythmic overdose. J Toxicol Clin Toxicol 1990;28:433-44
10. Pearigen PD, Benowitz NL. Poisoning due to calcium antagonists. Experience with verapamil, diltiazem, and nifedipine. Drug Saf 1991;6:408-30
11. Baud FJ, Sabouraud A, Vicaut E, et al. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med 1995;332:642-5
12. Loubieres Y, Vieillard-Baron A, Beauchet A, et al. Echocardiographic evaluation of left ventricular function in critically ill patients: dynamic loading challenge using medical antishock trousers. Chest 2000;118:1718-23
13. Colan SD, Borow KM, Neumann A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility. J Am Coll Cardiol 1984;4:715-24
14. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005;7:E609-24
15. Bryson SM, Whiting B, Lawrence JR. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. Br J Clin Pharmacol 1978;6:409-19
16. Lima JJ, Boudoulas H. Stereoselective effects of disopyramide enantiomers in humans. J Cardiovasc Pharmacol 1987;9:594-600
17. Francheteau P, Steimer JL, Merdjan H, et al. A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J Pharmacokinet Biopharm 1993;21:489-514
18. Upton RN, Ludbrook GL. Pharmacokinetic-pharmacodynamic modeling of the cardiovascular effects of drugs: method development and application to magnesium in sheep. BMC Pharmacol 2005;5:5
19. Friberg LE, Isbister GK, Hackett LP, et al. The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn 2005;32:571-605
20. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 2003;31:510-8
21. Jang IJ, Yu KS, Shon JH, et al. Pharmacokinetic/pharmacodynamic evaluation of a novel potassium channel opener, SKP450, in healthy volunteers. J Clin Pharmacol 2000;40:752-61
22. Bellissant E, Giudicelli JF. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial hemodynamic effects in healthy volunteers. Br J Clin Pharmacol 1999;48:801-10
23. Dartois C, Brendel K, Comets E, et al. Overview of model-building strategies in population PK/PD analyzes: 2002-2004 literature survey. Br J Clin Pharmacol 2007;64:603-12
24. Pérez-Urizar J, Granados-Soto V, Flores-Murrieta FJ, et al. Pharmacokinetic-pharmacodynamnic modeling: why? Arch Med Res 2000;31:539-45
25. Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev 2006;58:1326-56
26. Danhof M, de Jongh J, De Lange EC, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Ann Rev Pharmacol Toxicol 2007;47:357-400
27. Kappel F, Peer RO. A mathematical model for fundamental regulation processes in the cardiovascular system. J Math Biol 1993;31:611-31
28. Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985;313:474-9
29. Urtizberea M, Rochdi M, Sabouraud A, et al. Relationship between red blood cell potassium and plasma digitoxin concentrations in intoxicated patients. Pharmacol Toxicol 1991;68:237-42
30. Urtizberea M, Sabouraud A, Baud F, et al. Concepts for toxicokinetic-toxicodynamic modeling in clinical toxicology: application to acute cardiac glycoside intoxications. Arch Toxicol 1992;15:253-6
31. Mandema JW, Wada DR. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J Pharmacol Exp Ther 1995;275:1185-94
32. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25:358-71
33. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21:457-78
34. Mandema JW, Tuk B, van Steveninck AL, et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715-28
35. Isbister GK, Friberg LE, Hackett LP, Duffull SB. Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal. Clin Pharmacol Ther 2007;81:821-7
36. Baud FJ, Borron SW, Bismuth C. Modifying toxicokinetics with antidotes. Toxicol Lett 1995;82-83:785-93
37. Bismuth C, Gaultier M, Conso F, Efthymiou ML. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol 1973;6:153-62
38. Eddleston M, Ariaratnam CA, Sjöström L, et al. Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital. Heart 2000;83:301-6
39. Weiss M, Kang W. Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding. Pharm Res 2004;21:231-6
40. Kurzawski M, Bartnicka L, Florczak M, et al. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep 2007;59:107-11
41. Ballantyne B, Marrs TC. Postmortem features and criteria for the diagnosis of acute lethal cyanide poisoning. In: Ballantyne B, Marrs TC, editors, Clinical and experimental toxicology of cyanides. Bristol: John Wright; 1987. p. 217-47
42. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007;64:192-7
43. Mégarbane B, Bloch V, Deye N, Baud FJ. Pharmacokinetic/ pharmacodynamic modeling of cardiac toxicity in venlafaxine overdose. Intensive Care Med 2007;33:195-6
44. Blythe D, Hackett LP. Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999;18:309-13
45. Jonker DM, Kenna LA, Leishman D, et al. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther 2005;77:572-82
46. Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modeling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 2006;61:177-90
47. Isbister GK, Friberg LE, Duffull SB. Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Intensive Care Med 2006;32:1060-5
48. Nielsen-Kudsk JE, Askholt J. Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. Pharmacol Toxicol 1988;63:183-8
49. Mangoni AA. Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations. Drugs Aging 2005;22:913-41
50. Sowinski KM, Forrest A, Wilton JH, et al. Effect of ageing on atenolol pharmacokinetics and pharmacodynamics. J Clin Pharmacol 1995;35:807-14
51. Fagiolino P. The influence of cardiac output distribution on the tissue/ plasma drug concentration ratio. Eur J Drug Metab Pharmacokinet 2002;27:79-81
52. Ogungbenro K, Gueorguieva I, Majid O, et al. Optimal design for multiresponse pharmacokinetic-pharmacodynamic models: dealing with unbalanced designs. J Pharmacokinet Pharmacodyn 2007;34:313-31